Skip to main content

CombiMatrix Stands to Pocket $10M in Stock Offering

NEW YORK (GenomeWeb News) — CombiMatrix today said it stands to pocket $10 million when its parent company Acacia Research received commitments from “a select group of investors” to buy 9.8 million units of equity for $1.02 apiece
 
Each unit includes one Acacia Research-CombiMatrix share and a five-year warrant to buy 1.2 million shares at $.87 apiece. In afternoon trading today the stock was priced at $.88. The placement was handled by Oppenheimer & Co.
 
Acacia did not disclose how CombiMatrix plans to use the funding but said the firm is developing a platform to make semiconductor-based arrays for “identifying and determining roles of genes, gene mutations, and proteins.”

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.